{"id":"NCT05046795","sponsor":"Mylan Pharma UK Ltd.","briefTitle":"Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)","officialTitle":"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-10","primaryCompletion":"2023-07-26","completion":"2023-07-26","firstPosted":"2021-09-16","resultsPosted":"2024-11-01","lastUpdate":"2024-11-01"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"Revefenacin 175 mcg in 3 ML Inhalation Solution","otherNames":[]},{"type":"DRUG","name":"Placebo inhalation solution QD","otherNames":[]}],"arms":[{"label":"Revefenacin inhalation solution 175 mcg QD.","type":"EXPERIMENTAL"},{"label":"Placebo inhalation solution QD.","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a phase III clinical study to assess the efficacy and safety of Revefenacin inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to placebo in a population of Chinese subjects with moderate to very severe COPD.","primaryOutcome":{"measure":"Trough FEV1 on Day 85","timeFrame":"Baseline and Day 85","effectByArm":[{"arm":"Revefenacin Inhalation Solution 175 mcg QD.","deltaMin":55.12,"sd":23.974},{"arm":"Placebo Inhalation Solution QD.","deltaMin":-95.78,"sd":24.504}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":35,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":129},"commonTop":["COPD","COVID-19","Upper respiratory tract infection","Chest discomfort","Dyspnea"]}}